Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ALN1
|
|||
| Drug Name |
CWHM-12
|
|||
| Synonyms |
cwhm-12; CWHM12; 1564286-55-0; (3S)-3-(3-bromo-5-(tert-butyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid; CHEMBL3319237; CWHM 12; SCHEMBL15475283; GTPL10495; AOB2397; EX-A850; (3S)-3-(3-bromo-5-tert-butylphenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid; BDBM50497716; MFCD28385850; AKOS027423695; CS-3537; NCGC00390566-03; AS-16717; HY-18644; J-690209; (3S)-3-(3-bromo-5-tert-butylphenyl)-3-(2-(3-hydroxy-5-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-ylamino)benzamido)acetamido)propanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatic fibrosis [ICD-11: DB93.0; ICD-10: K74.0; ICD-9: 709.2] | Preclinical | [1] | |
| Pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1] | Preclinical | [1] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H32BrN5O6
|
|||
| Canonical SMILES |
CC(C)(C)C1=CC(=CC(=C1)C(CC(=O)O)NC(=O)CNC(=O)C2=CC(=CC(=C2)O)NC3=NCC(CN3)O)Br
|
|||
| InChI |
1S/C26H32BrN5O6/c1-26(2,3)16-4-14(5-17(27)8-16)21(10-23(36)37)32-22(35)13-28-24(38)15-6-18(9-19(33)7-15)31-25-29-11-20(34)12-30-25/h4-9,20-21,33-34H,10-13H2,1-3H3,(H,28,38)(H,32,35)(H,36,37)(H2,29,30,31)/t21-/m0/s1
|
|||
| InChIKey |
YDHAGPCZRFQPOI-NRFANRHFSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Integrin alpha-V/beta-6 (ITGAV/B6) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.